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Retinitis pigmentosaMitochondrial μ-calpain initiates apoptosis-inducing factor (AIF)-dependent apoptosis in retinal photorecep-
tor degeneration. Mitochondrial μ-calpain inhibitors may represent therapeutic targets for the disease. There-
fore, we sought to identify inhibitors of mitochondrial calpains and determine their effects in Royal College of
Surgeons' (RCS) rats, an animal model of retinitis pigmentosa (RP). We synthesized 20-mer peptides of the
C2-like (C2L) domain of μ-calpain. Two μ-calpain peptides N2 and N9 inhibited mitochondrial μ-calpain activ-
ity (IC50; 892 and 498 nM, respectively), but not other proteases. Western blotting showed that 50 μM of
both μ-calpain peptides caused speciﬁc degradation of mitochondrial μ-calpain. Three-dimensional structure
of calpains suggested that the peptides N2 and N9 corresponded to the regions forming salt bridges between
the protease core domain 2 and the C2L domain. We determined the inhibitory regions of μ-calpain peptides
N2 and N9 using 10-mers, and one peptide, N2-10-2, inhibited the activity of mitochondrial μ-calpain (IC50;
112 nM). We next conjugated the peptide N2-10-2 to the C-terminal of HIV-1 tat (HIV), a cell-penetrating
peptide. Using isolated rat liver mitochondria, 50 μM HIV-conjugated μ-calpain N2-10-2 peptide (HIV-Nμ,
IC50; 285 nM) signiﬁcantly inhibited AIF truncation. The intravitreal injection of 20 mM HIV-Nμ also
prevented retinal photoreceptor apoptosis determined by TUNEL staining, and preserved retinal function
assessed by electroretinography in RCS rats. Topical application of 40 mM HIV-Nμ also prevented apoptosis
of retinal photoreceptors in RCS rats. Our results demonstrate that HIV-Nμ, a peptide inhibitor of mitochon-
drial μ-calpain, offers a new modality for treating RP.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Calpains are Ca2+-activated neutral cysteine proteases that mod-
ulate many cellular functions, including cell motility, differentiation,
proliferation, apoptosis, signal transduction and gene expression by
limited proteolysis of speciﬁc substrates [1–5]. Three calpain
isoforms, viz. μ- and m-calpains and calpain-10, are localized in the
cytoplasm and mitochondria [6]. Mitochondrial calpains initiate
apoptosis-inducing factor (AIF)-mediated apoptosis in vitro [7–12],
and in animal models of retinal degeneration, cerebral ischemia and
cardiac ischemia [13–16]. After truncation of AIF by mitochondrialry and Molecular Biology, Fac-
, 3 Bunkyo-cho, Hirosaki 036‐
ro).
rights reserved.μ-calpain, AIF can translocate from the mitochondria to the nucleus
where it facilitates chromatin condensation and large-scale DNA frag-
mentation [17]. AIF-induced apoptosis is involved in many diseases/
biological activities, including epilepsy [18], oxidative stress [19],
neuronal excitotoxicity [20], Alzheimer disease [21] and cisplatin
nephrotoxicity [22]. Therefore, we hypothesized that inhibition of mi-
tochondrial calpains could represent a treatment target for many dis-
eases associated with AIF-dependent apoptosis.
Retinitis pigmentosa (RP) is a hereditary disease involving retinal
degeneration that is characterized by night blindness and constriction
of peripheral visual ﬁelds, and eventually results in severe visual dis-
turbance. In the early stages of the disease, the rod photoreceptors
degenerate, which is followed by dysfunction of the cone photorecep-
tors. Although molecular genetic studies have revealed that at least
47–50 genes are involved in or cause RP (Ret-Net: Disease Table.
http://www.sph.uth.tmc.edu/retnet/disease.htm), there are currently
no effective treatments for RP.
Table 1
μ-calpain peptide N2 and N9 segments.
Name Sequence # A.A. M.W. (Da)
N2-20 I CNL TPDALKSRTLRNWNTT 20 2317.65
N2-10-1 I CNL TPDALK 10 1087.30
N2-10-2 PDALKSRTLR 10 1187.30
N2-10-3 SRTLRNWNTT 10 1248.36
N9-20 SRAQSEHF I NLREVSNRIRL 20 2425.74
N9-10-1 SRQSEHF IN 10 1188.27
N9-10-2 EHF I NLREVS 10 1243.88
N9-10-3 LREVSNRIRL 10 1255.49
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drial calpain activity in the treatment of retinal degeneration using an
animal model of RP, the Royal College of Surgeons' (RCS) rat [23–26].
These rats carry a mutation in the Mertk gene, which is normally
expressed in the retinal pigment epithelium (RPE) [27]. Under phys-
iological conditions, photoreceptor outer segments are continuously
renewed by phagocytosis of RPE and are regenerated by photorecep-
tors. In RCS rats, phagocytosis is impaired and fragments of
undegraded photoreceptor outer segments accumulate in the space
between the outer segments and RPE [23]. Several reports have
suggested that intracellular Ca2+ is involved in photoreceptor degen-
eration in the RCS rat and in other animal models, such as retinal de-
generation (rd1) mice and retinal degeneration slow (rds) mice
[28–30]. We previously reported that mitochondrial calpains are acti-
vated in the early stage of retinal photoreceptor apoptosis in RCS rats
[15]. Intravitreal injection of calpain inhibitors, ALLN and PD150606,
at the time of mitochondrial calpain activation prevented nuclear
translocation of AIF and photoreceptor apoptosis. However, inhibition
of mitochondrial and cytosolic calpains may inﬂuence many physio-
logic cellular functions. Therefore, in the present study, we sought
to identify and characterize potent and speciﬁc inhibitors of mito-
chondrial calpains.
To inhibit themitochondrial calpains, we focused on C2 domain-like
(C2L) domain (previously called domain III). The μ- and m-calpains are
heterodimers composed of a large ~80-kDa catalytic subunit (CAPN1
and CAPN2, respectively) and a small ~30-kDa regulatory subunit
(CAPNS1, common to both calpains) [1,31]. The large and small sub-
units contain several domains: the N-terminal helix of CAPN1 and
CAPN2 (previously called domain I) and the N-terminal Gly-rich (GR)
domain of CAPNS1 (domain V) are autolyzed upon activation. The pro-
tease (CysPc) domain consists of two protease core domains PC1 and
PC2 (domains IIa/IIb or I/II), which are well-conserved among the 15
calpain isoforms. The C-terminal domains of both subunits contain
ﬁve sets of EF-hand Ca2+-binding motif, and are, thus, called penta-
EF-hand (PEF(L) and PEF(S)) domains (domains IV and VI). Finally,
the C2L domain has a 3D structure similar to C2-domain, although
its functions remain to be elucidated. We previously reported that
mitochondrial μ-calpain is associated with the molecular chaperones
ERp57 [10]. Inhibition of ERp57 caused a loss of stability and proteolytic
degradation of the large subunit of mitochondrial μ-calpain [10]. There-
fore, in the present study, we hypothesized that μ-calpain peptides
could competitively inhibit these interactions (i.e., mitochondrial
μ-calpain–ERp57), and induce a loss of stability and activity of these
calpains. Although the binding regions between the mitochondrial
calpains and the molecular chaperones have not been identiﬁed, we
previously found that an anti-m-calpain C2L domain antibody did not
react with mitochondrial m-calpain [11]. This suggests that the
sequence of the C2L domain in mitochondrial m-calpain differs from
that of cytosolic m-calpain, and that mitochondrial chaperones speciﬁ-
cally bind to this domain. Although the differences of antibody reactiv-
ity between cytosolic and mitochondrial μ-calpains have not been
elucidated, we targeted the C2L domain in the present study because
the structures of μ- and m-calpains are analogous.
Therefore, the aims of the present study were to (1) identify and
characterize inhibitory peptides ofmitochondrial calpains and (2) to de-
termine whether the identiﬁed peptides could prevent AIF-dependent
apoptosis of retinal photoreceptor cells in RCS rats.
2. Materials and methods
2.1. Animals
All experimental procedures were designed to conform to the As-
sociation for Research in Vision and Ophthalmology (ARVO) State-
ment for Use of Animals in Ophthalmic Vision Research and the
Hirosaki University Guidelines for animal experiments. Sprague–Dawley (SD) rats were used to prepare liver cytosolic and mitochon-
drial fractions, and for partial puriﬁcation of cytosolic and mitochon-
drial calpains. RCS rats, an animal model of human RP, were used to
determine the effects of calpain peptide inhibitors on retinal photore-
ceptor apoptosis. SD rats and RCS (rdy−/−) rats were purchased from
Clea Japan, and were housed at the Hirosaki University Graduate
School of Medicine Animal Care Service Facility under a 12-h light
(50 lx illumination) and 12-h dark (b10 lx illumination) cycle. Care
was taken not to cause photoreceptor light damage to rats.2.2. Antibodies
The following antibodies were purchased: rabbit polyclonal anti-
bodies against μ-calpain PEF(L) (Sigma, C5611), anti-calpain small
subunit (CAPNS1) (Abcam, ab28237), anti-AIF (Abcam, ab1998),
anti-adenylate kinase 2 (Santa Cruz, sc-28786), anti-GAPDH (Santa
Cruz, sc-25778), anti-voltage-dependent anion-selective channel
(VDAC) (Calbiochem, PC548), anti-pyruvate dehydrogenase (Molecu-
lar Probes, Eugene, OR, A-21323), mouse monoclonal anti-trans-Golgi
network-46 (Abcam, ab2809), anti-HIV1 tat (Abcam, ab63957), rat
monoclonal anti-zonula occludens-1 (ZO-1; Chemicon, MAB1520),
and normal rabbit IgG (Santa Cruz).2.3. Synthesis of μ-calpain C2L domain peptides
We separately synthesized μ-calpain C2L domain peptides, as
shown in Tables 1 and 2. Each peptide was synthesized by the
ﬂuorenylmethyloxycarbonyl method using an automated peptide
synthesizer (Shimazdu PSSM-8; Shimazdu). The resulting peptides
were puriﬁed by reverse-phase HPLC using a C18 column (Jupiter
250 mm×10 mm; Phenomenex). The molecular weight and purity
of each peptide were conﬁrmed by MALDI-TOF mass spectrometry
with a Voyager RP-DE (Applied Biosystems), as previously described
[10]. No minor peaks were observed other than the correctly synthe-
sized peptide. The purity of each synthesized peptide was >95% esti-
mated on the relative absorbance by HPLC.2.4. Preparation of the liver cytosolic fraction and partial puriﬁcation of
cytosolic μ- and m-calpains
To purify cytosolic μ- andm-calpains, the liver cytosolic fractionwas
prepared from 8-week-old SD rats, as previously described [9]. The
resulting cytosolic fraction was dialyzed with buffer A (20 mM Tris–
HCl, pH 7.5 containing 140 mM NaCl, 1 mM EDTA, 1 mM EGTA and
5 mM 2-mercaptoethanol). Partial puriﬁcation of cytosolic μ- and
m-calpains was achieved via a three-column chromatographic proce-
dure, as previously described [9]. All chromatographic procedures
were performed at 4 °C with DEAE-Sepharose CL-6B, Sephacryl S-300
and Sepharose 6B columns (Amersham Pharmacia Biotech). The par-
tially puriﬁed cytosolic μ- and m-calpains were dialyzed with buffer A
and concentrated using Amicon PM-10 membrane (Millipore).
Table 2
Cell-penetrating peptide (CPP)-conjugated μ-calpain peptide N2-10-2.
Name Sequence A.A. M.W. (Da)
μ-N2-10-2 (HIV-Nμ) GRKKRRQRRRPPQ-PDALKSRTLR 23 2857.37
μ-N2-10-2 (HIV-Cμ) PDALKSRTLR-GRKKRRQRRRPPQ 23 2857.37
The indicated CPPs were conjugated to the N- or C-terminal regions of μ-calpain pep-
tide N2-10-2.
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fractions
Rat liver mitochondria and mitochondrial compartments were
prepared from 8-week-old SD rats, as previously described [9]. To
prevent contamination with cytosolic proteins, the mitochondrial
surface was treated with proteinase K [11]. The purity of the mito-
chondrial compartments was determined by immunoblotting with
anti-VDAC antibody for the mitochondrial outer membrane, anti-
adenylate kinase 2 for the intermembrane space (IMS), anti-AIF anti-
body for the inner membrane, anti-pyruvate dehydrogenase antibody
for the matrix, anti-GAPDH antibody for the cytosolic fraction,
anti-ZO-1 for the plasma membrane, anti-calnexin for the ER, and
anti-trans-Golgi network-38 for the Golgi apparatus [11].
2.6. Partial puriﬁcation of mitochondrial μ- and m-calpains from the rat
liver mitochondrial IMS
Mitochondrial μ- and m-calpains were puriﬁed as described for
cytosolic μ- and m-calpains. All chromatographic procedures were
performed at 4 °C with DEAE-Sepharose CL-6B, Sephacryl S-300 and
Sepharose 6B columns, as previously described [9,11]. The partially
puriﬁed mitochondrial μ- and m-calpains were dialyzed with buffer
A and concentrated using an Amicon PM-10 membrane.
2.7. Calpain activity assay
Various concentrations of μ-calpain peptides were incubated with
50 μl of rat liver IMS proteins or partially puriﬁed calpains at 4 °C for
4 h. Calpain activity was assayed using succinyl-Leu-Tyr-7-amino-
4-methylcoumarin (Suc-Leu-Tyr-AMC; BACHEM) as a substrate [9].
Suc-Leu-Tyr-AMC is cleaved by calpain to form a ﬂuorescent product.
The assay was performed as follows: 50 μl of each sample containing
various concentrations of the μ-calpain peptides (1 nM–100 μM) was
added to 450 μl of substrate solution (100 mM Tris–HCl, pH 7.5,
10 mM 2-mercaptoethanol, 100 mM KCl, 5 mM CaCl2 containing
20 μM Suc-Leu-Tyr-AMC) and incubated at 25 °C. After incubation
for 20 min, 500 μl of 100 mM EDTA was added and the mixture
was boiled at 80 °C for 3 min to stop the reaction. The ﬂuorescence
intensity of each sample was measured with a ﬂuorophotometer (ex-
citation: 380 nm; emission: 460 nm) and calpain activity was deﬁned
as the change in ﬂuorescence/minute.
2.8. SDS-PAGE, native-PAGE and western blotting
IMS proteins incubated with each μ-calpain peptide were
subjected to SDS-PAGE on 10% SDS-polyacrylamide gels (40 μg pro-
tein per lane). Nondenaturing (native) PAGE was carried out to eval-
uate protein–protein interactions using a modiﬁed zymography
method, as previously described [10]. We used 7.5% polyacrylamide
gel without casein as a separating gel. After SDS-PAGE or native-
PAGE, western blotting was performed as previously described [10].
After electrophoretic transfer of the proteins to a nitrocellulose mem-
brane, the membranes were treated with the primary antibodies
followed by horseradish peroxidase-conjugated goat anti-rabbit or
rabbit anti-goat IgG secondary antibodies (DAKO). The immunoreac-
tive signals were developed with an enhanced chemiluminescencewestern blotting detection kit (Amersham Biosciences) and quanti-
ﬁed with a luminescent image analyzer (LAS-3000; Fujiﬁlm Co.).
2.9. Cathepsin activity assay
To determine the speciﬁcity of μ-calpain peptides, we examined
the effects of μ-calpain peptides on the enzymatic activities of ca-
thepsin, papain and proteasome. Cathepsin activity was assayed
using a cathepsin ﬂuorogenic substrate (Z-Phe-Arg-AMC; Biomol)
by the method reported by Tavares et al. [32]. Brieﬂy, 50 nM of
human recombinant cathepsin L (BioVision) and various concentra-
tions of the μ-calpain peptides (1 nM–100 μM) were added to the
assay solution (100 mM NaOAc–HCl, pH 5.5, 120 mM NaCl, 10 mM
dithiothreitol) in a total volume of 1 ml. The solutions were
preincubated at 4 °C for 4 h and the reaction was initiated by the ad-
dition of 20 μMZ-Phe-Arg-AMC. After incubating at 25 °C for 20 min,
the mixtures were boiled at 80 °C for 3 min to stop the reaction. The
ﬂuorescence intensity of each sample was measured using a
ﬂuorophotometer (excitation: 365 nm; emission: 440 nm) and ca-
thepsin activity was deﬁned as the change in ﬂuorescence/minute.
2.10. Papain activity assay
Papain activity was assayed using themethod reported byMarcia et
al. [33]with Bz-Arg-AMC (Bachem) as the ﬂuorescent substrate. Brieﬂy,
50 nMpapain (AppliChem) and various concentrations of the μ-calpain
peptides (1 nM–100 μM) were added to assay solution (100 mM sodi-
um phosphate, pH 6.5, 1 mM EDTA, 1 mM dithiothreitol) in a total vol-
ume of 1 ml. The solutions were preincubated at 4 °C for 4 h and the
reactionwas initiated by the addition of 20 μMBz-Arg-AMC. After incu-
bating at 37 °C for 20 min, the mixtures were boiled at 80 °C for 3 min
to stop the reaction. The ﬂuorescence intensity of each sample was
measured with a ﬂuorophotometer (excitation: 380 nm; emission:
440 nm) and papain activity was deﬁned as the change in ﬂuores-
cence/minute.
2.11. Proteasome activity assay
For the proteasome inhibition assay, we used the ﬂuorogenic sub-
strate Suc-Leu-Leu-Val-Tyr-AMC (Suc-LLVY-AMC; A. G. Scientiﬁc, San
Diego, CA), as previously described [34]. Brieﬂy, 1 nM of human
proteasome 20S (Biomol) and various concentrations of the μ-calpain
peptides (1 nM–100 μM) were added to the assay solution (20 mM
Tris–HCl, pH 8.0, 0.5 mM EDTA and 0.035% SDS) in a total volume of
1 ml. The solutions were preincubated at 4 °C for 4 h and the reaction
was initiated by the addition of 20 μM Suc-LLVY-AMC. After incubating
at 25 °C for 20 min, themixtures were boiled at 80 °C for 3 min to stop
the reaction. The ﬂuorescence intensity of each sample was measured
with a ﬂuorophotometer (excitation: 360 nm; emission: 460 nm) and
proteasome activity was deﬁned as the change in ﬂuorescence/minute.
2.12. Effects of the μ-calpain peptide inhibitor on AIF cleavage in isolated
rat liver mitochondria
Isolated mitochondria from 8-week-old SD rat livers were
resuspended in 20 mM Tris–HCl, pH 7.5, 0.25 M sucrose, and 5 mM
2-mercaptoethanol. Then, the mitochondrial suspension was treated
with 50 μM of the μ-calpain peptide (HIV-Nμ), 150 μM PD150606 or
50 μM calpeptin at 4 °C for 4 h. Next, 1 mM CaCl2 was added to the
suspension and incubated at 37 °C for 30 min. After incubation, prote-
ase inhibitor cocktail (Roche Applied Science) and 1% Triton X-100
were added to each sample. The samples were centrifuged at
15,000×g for 20 min at 4 °C, and the supernatants were subjected to
western blotting to determine whether AIF was truncated.
1786 T. Ozaki et al. / Biochimica et Biophysica Acta 1822 (2012) 1783–17952.13. Effects of the μ-calpain peptide inhibitor on retinal photoreceptor
cell death in RCS rats
The effects of μ-calpain peptide inhibitors on retinal photoreceptor
cell death in RCS rats were determined as previously described [15]. A
total of 12 RCS rats (25 days old) were anesthetized by intramuscular
injection of ketamine (80–125 mg/kg) and xylazine (9–12 mg/kg).
After topical application of 0.02% oxybuprocaine hydrochloride to
the cornea, each animal received an intravitreal injection of 2 μl of
4 mM PD150606, or 20 mM HIV-Nμ in PBS (0.14 M NaCl and
10 mM phosphate buffer, pH 7.4), or the same volume of PBS as a
control (n=9 per group). The solutions were injected with a Hamil-
ton syringe with a 30-gage needle through the area of the ciliary
body into the vitreous cavity. The rats were killed 3 days after
injection. Eyes were enucleated and prepared for TUNEL staining.
2.14. TUNEL staining
To determine retinal photoreceptor cell death, cleavage of DNA
was visualized in situ by TUNEL staining. The eyes of inhibitor-
treated RCS rats were enucleated and embedded in OCT compound
(Sakura). Cryosections (5 μm thick) were cut superior or inferior to
the equator plane containing the optic disk and the central portion
of the eye ball, respectively. The numbers of TUNEL-positive cells
were counted in 20 sections per eye from nine eyes from each group.
After washing with PBS, we performed TUNEL staining using In Situ
Apoptosis Detection Kits (Takara) according to the manufacturer's in-
structions. Sections were counterstained with DAPI. Immunoﬂuores-
cent images were acquired by laser scanning confocal microscopy
(FV1000-D; Olympus).
2.15. Immunohistochemistry
The enucleated eyes were ﬁxed in 4% PFA in PBS, pH 7.4, for
20 min at room temperature. The anterior segments were removed
and posterior eyecups were placed in the same ﬁxative overnight at
4 °C. Eyecups were cryoprotected for 4 h in 10% then 20% sucrose in
PBS, and then frozen in OCT compound. Cryosections (5 μm thick)Fig. 1. Sequences of the synthetic peptides of μ-calpain C2L domain of rat μ-calpain large sub
region of C2L domain of CAPN1. The shaded sequences represent three aas that overlappe
under the sequence of CAPN1. The accession numbers for CAPN1 is NP_062025.1.were made superior or inferior to the equator plane containing
the optic disk and the central portion of the eye ball. The sections
were rinsed in PBS and blocked with 1% skim milk in PBS plus
Tween (PBS-T) for 2 h at room temperature. Sections were incubated
overnight at 4 °C with the primary antibody (mouse monoclonal
anti-HIV1 tat) diluted in 1% skim milk in PBS-T. Sections were then
washed with PBS-T and incubated with tetramethylrhodamine iso-
thiocyanate isomer R (TRITC)-conjugated rabbit anti-mouse IgG
(DAKO, R0270, 1:200) overnight at 4 °C. Sections were washed
with PBS-T and nuclei were counterstained with DAPI. Immuno-
ﬂuorescent images were acquired by laser scanning confocal
microscopy.2.16. Electroretinography (ERG)
The preparation, recording technique and measurement of ERG
responses are described in more detail elsewhere [35]. Brieﬂy, RCS
rats (3–5 weeks old; weighing 150–200 g) were used in this study.
Three days after intravitreous injection of HIV-conjugated μ-calpain
peptides (HIV-Nμ), the rats were moved to an electrically shielded
room, anesthetized, and laid on their side on a heating pad (at
37 °C). The head was ﬁxed in place with surgical tape, and the rats
were dark-adapted for 24 h. The pupils were dilated with 0.5%
tropicamide eye drops. ERGs were recorded with a contact electrode
equipped with a suction apparatus to ﬁt on the cornea (Kyoto Contact
Lens Co.). A grounding electrode was placed on the ear. Responses to a
200-ms duration white ﬂash (3.5×102 lx) were recorded (Neuropack,
model MES-3102; Nihon Kohden). The a-wave amplitude was deter-
mined as the baseline to the bottom of the a-wave. The b-wave ampli-
tude was determined as the bottom of the a-wave to the top of
b-wave. ERG amplitudes are shown as means±SD.2.17. Statistical analysis
Student's t test or ANOVAwas used to statistically compare results.
Experiments were performed in triplicate to conﬁrm reproducibility.unit (CAPN1). The peptides were synthesized for every 20 residues from the N-terminal
d in each synthesized peptide. The aa sequences of 14 synthetic peptides were shown
AB
C
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3.1. Calpain inhibitory activity of synthetic peptide
We separately synthesized 14 peptides derived from μ-calpain C2L
domain as 20 aa residues (Fig. 1). Three aas overlapped and were syn-
thesized in each 20-mer peptide. We tested the inhibitory potency of
these peptides against mitochondrial calpains using the rat liver mi-
tochondrial IMS and assayed calpain activity (Fig. 2). Two μ-calpain
peptides signiﬁcantly inhibited IMS calpain activity. The μ-calpain
peptides were peptides 2 and 9 from the N-terminal region of C2L
domain (N2 and N9).
3.2. Speciﬁcity of μ-calpain peptides N2 and N9
We examined the speciﬁcity of μ-calpain peptides N2 and N9
against several proteases, including rat liver cytosolic μ- and
m-calpain, mitochondrial μ- and m-calpain, human recombinant ca-
thepsin L, proteasome puriﬁed from human erythrocytes, and papain.
Both μ-calpain peptides potently inhibited mitochondrial μ-calpain
(Fig. 3A and B). Neither peptide affected the activities of cathepsin
L, proteasome or papain. We assayed calpain activity using partially
puriﬁed mitochondrial μ-calpain in the presence of various concen-
trations of peptides N2 and N9 (Fig. 3C). The peptides N2 and N9
inhibited the mitochondrial μ-calpain activity in a dose-dependent
manner. The IC50 values of peptides N2 and N9 were 892 and
498 nM, respectively.
3.3. Effects of μ-calpain peptides N2 and N9 on mitochondrial calpains
We examined whether the μ-calpain peptides N2 and N9 could
induce the degradation of mitochondrial μ-calpains (Fig. 4). We used
μ-calpain peptides N4, N6, N10, and N12 as a control. SDS-PAGE and
western blotting showed that μ-calpain peptides N2 and N9 caused
the degradation of mitochondrial μ-calpain (Fig. 4A). Native-PAGE and
western blotting showed that μ-calpain peptides N2 and N9 induced
the loss of the mitochondrial μ-calpain bands (Fig. 4B). These results
suggest that μ-calpain peptides N2 and N9 caused the degradation of
mitochondrial μ-calpain.
3.4. Determination of the inhibitory regions in μ-calpain C2L domain
To determine the inhibitory regions of μ-calpain peptides, we
spliced the 20-mer μ-calpain peptides N2 and N9 into 10-merFig. 2. Inhibition of mitochondrial calpain activity by μ-calpain peptides. Each peptide
(ﬁnal concentration; 50 μM)was pretreated with 25 μg of mitochondrial intermembrane
space (IMS) protein, as described in the Materials and methods. Two 20-mer peptides
from the N-terminal region of C2L domain (N2 and N9) signiﬁcantly inhibited mitochon-
drial calpain activity. All data are expressed as means±SD (n=3). *Pb0.05 and **Pb0.01
versus vehicle (t-test).
Fig. 3. Speciﬁcity and inhibition curve of μ-calpain peptides N2 and N9. Peptide speci-
ﬁcity was tested by incubating each 50 μM each peptide with 25 μg of partially puriﬁed
rat liver cytosolic μ- and m-calpain, mitochondrial μ- and m-calpain, human recombi-
nant cathepsin L, proteasome 20S (puriﬁed from human erythrocytes), and papain
(puriﬁed from papaya). All data are expressed as means±SD (n=3). (A) μ-Calpain
peptide N2 potently inhibited mitochondrial μ-calpain. (B) μ-Calpain peptide N9 also
inhibited mitochondrial μ-calpain. None of the peptides tested affected the activity of
cathepsin L, proteasome or papain. (C) Inhibition curve of μ-calpain peptides N2 (●)
and N9 (○). Partially puriﬁed rat liver mitochondrial μ-calpain (25 μg protein) was
assayed in the presence of various concentrations of peptides N2 and N9 as described
in the “Materials and methods” section. The IC50 values of peptides N2 and N9 were
892 and 498 nM, respectively.peptides, as shown in Table 1, and determined their inhibitory poten-
cies (Fig. 5A). One 10-mer peptide (N2-10-2) inhibited the activity of
IMS calpains, whereas the 10-mer peptides of N9 had no inhibitory
effects. We next tested the speciﬁcity of N2-10-2 against seven prote-
ases (rat liver cytosolic μ- and m-calpain, mitochondrial μ- and
m-calpain, human recombinant cathepsin L, proteasome puriﬁed
from human erythrocytes and papain). The μ-calpain peptide
N2-10-2 strongly inhibited mitochondrial μ-calpain and moderately
inhibited mitochondrial m-calpain, but not the other proteases
Fig. 4. Effects of μ-calpain peptides N2 and N9 on mitochondrial calpains. We used
μ-calpain peptides N4, N6, N10, and N12 as a control. Each peptide (ﬁnal concentration;
50 μM) was pretreated with mitochondrial intermembrane space (IMS) protein (40 μg
protein). The effects of the peptides on mitochondrial μ-calpain were examined by
SDS-PAGE and immunoblotting (A). Complex formation was analyzed by native-PAGE
and immunoblotting (B). Data are representative of three independent experiments.
(A) μ-Calpain peptides N2 and N9 induced the degradation or autolysis of the large
subunit of mitochondrial μ-calpain. The solid and open arrowheads indicate the 80-kDa
intact and 78- or 76-kDa autolyzed large subunit of μ-calpain, respectively. (B) The inten-
sity of the band corresponding to mitochondrial μ-calpain was reduced by pretreatment
with μ-calpain peptides N2 and N9.
C
B
A
Fig. 5. Identiﬁcation of the inhibitory regions of μ-calpain peptides N2 and N9. Speciﬁc
segments of each peptide (ﬁnal concentration; 50 μM) were incubated with 25 μg of
rat liver mitochondrial intermembrane (IMS) protein (A) or the indicated proteases
(B). Data are expressed as means±SD (n=3). (A) Inhibitory effects of the μ-calpain
peptides N2 and N9 segments listed in Table 1. μ-Calpain peptides N2-20 and N9-20
inhibited enzyme activity by ~50% and ~45%, respectively. One of the N2-10 peptides,
N2-10-2, inhibited enzyme activity by ~85%. The N9-10 peptide showed no inhibitory
activity. (B) Speciﬁcity of μ-calpain peptide N2-10-2. The peptide N2-10-2 strongly
inhibited mitochondrial μ-calpain and moderately inhibited mitochondrial m-calpain.
(C) Inhibition curve of μ-calpain peptide N2-10-2. Partially puriﬁed rat liver mitochon-
drial μ-calpain (25 μg protein) was assayed in the presence of various concentrations of
N2-10-2 as described in the “Materials and methods” section. The IC50 value of this
peptide was 112 nM.
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tially puriﬁed mitochondrial μ-calpain (Fig. 5C). The peptide
N2-10-2 inhibited the mitochondrial μ-calpain activity in a dose-
dependent manner. The IC50 value of the peptide was 112 nM,
which was higher than those of peptides N2 (IC50; 892 nM) and N9
(IC50; 498 nM).
3.5. Conjugation the μ-calpain peptide N2-10-2 to cell-penetrating
peptide (CPP)
To transport the peptides across the plasma and mitochondrial
outer membranes, we conjugated μ-calpain peptide N2-10-2 to HIV-1
tat peptide (HIV) [21,36–38] as a CPP at the N- or C-terminal region
of N2-10-2 (Table 2). We evaluated the inhibitory effects of the
resulting μ-calpain peptide–HIV complexes with mitochondrial
IMS fraction. As shown in Fig. 6A, μ-calpain peptide N2-10-2 bear-
ing HIV peptide on its N-terminal region (HIV-Nμ) showed inhibi-
tory effects. The μ-calpain peptide bearing HIV on its C-terminal
region (HIV-Cμ) showed a reduction in inhibitory activity by ~30% com-
pared with the unconjugated peptide. HIV alone did not have an effecton mitochondrial calpain activity. We determined enzymatic kinetics
of peptides N2, N2-10-2, HIV-Nμ, and HIV-Cμwith partially puriﬁedmi-
tochondrial μ-calpain (Fig. 6B). The HIV-Nμ inhibited themitochondrial
μ-calpain activity in a dose-dependent manner. The IC50 value of the
HIV-Nμ was 285 nM, which was lower than that of peptide N2-10-2
(IC50; 112 nM), but higher than those of peptides N2 and N9. In con-
trast, HIV-Cμ did not show signiﬁcant inhibition of mitochondrial
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experiment, HIV-Nμ inhibited mitochondrial μ-calpain activity by
~75% and mitochondrial m-calpain activity by ~40% (Fig. 6C).Fig. 6. Effects of cell-penetrating peptide (CPP)-conjugated μ-calpain peptide N2-10-2
on the activity of mitochondrial calpains. The CPP-conjugated peptides (ﬁnal concen-
tration; 50 μM) listed in Table 2 were pretreated with 25 μg of rat liver mitochondrial
intermembrane space (IMS) protein (A), partially puriﬁed mitochondrial μ-calpain (B),
or the indicated proteases (C). Data are expressed as means±SD (n=3). (A) μ-Calpain
peptide N2-10-2 inhibited enzyme activity by ~70%. HIV-conjugated N2-10-2 at the
N-terminal region of N2-10-2 (HIV-Nμ) inhibited enzyme activity by ~55%.
HIV-conjugated N2-10-2 at the C-terminal region of N2-10-2 (HIV-Cμ) inhibited mito-
chondrial calpain activity by only ~40%. HIV alone did not affect the activity of
mitochondrial calpains. (B) Inhibition curve of N2, N2-10-2, HIV-Nμ and HIV-Cμ. Par-
tially puriﬁed rat liver mitochondrial μ-calpain was assayed in the presence of various
concentrations of N2, N2-10-2, HIV-Nμ and HIV-Cμ as described in the “Materials and
methods” section. The IC50 value of HIV-Nμ was 197 nM. (C) Speciﬁcity of HIV-Nμ.
HIV-Nμ inhibited mitochondrial μ-calpain activity by ~75% and mitochondrial
m-calpain activity by ~40%.3.6. HIV-Nμ inhibits AIF truncation
We tested whether HIV-Nμ prevented the proteolytic processing
of AIF. In this experiment, isolated rat liver mitochondria were
preincubated with 50 μM HIV-Nμ, as described in the Materials and
methods. The solubilized mitochondrial proteins were separated by
SDS-PAGE, and the truncation of AIF was examined by immunoblot-
ting (Fig. 7). Proteolytic processing of AIF occurred in the presence
of Ca2+, and was completely blocked by calpeptin and PD150606.
Treatment with HIV-Nμ also signiﬁcantly reduced truncation of AIF.
3.7. Alignment analysis of the μ-calpain peptides N2 and N9
We performed sequence alignment of the human μ-calpain cata-
lytic subunit (CAPN1) with other isoforms of the calpain superfamily
to observe the homology of the μ-calpain peptides N2 and N9 (Fig. 8).
Sequences corresponding to the PC2 and C2L domains are shown. The
identity of each amino acid residue among isoforms is indicated by ei-
ther reversed letters (100%), orange marking (≥50%), or none
(b50%). Although the PC2 domain was highly conserved, there was
much heterogeneity in the C2L domain. μ-Calpain peptide N2 corre-
sponds to the linker region between the PC2 and C2L domains. The
homology of the N2 and N9 peptide regions was relatively low be-
tween CAPN1 and other calpain isoforms.
3.8. Identiﬁcation of the μ-calpain N2 and N9 peptide regions in the 3D
structure of active human m-calpain
We next sought to identify the regions targeted by the inhibitory
peptides in the 3D structure of active human m-calpain (PDB acces-
sion number: 3DF0) (Fig. 9). The large catalytic subunit contains
CysPC (red), C2L (silver) and Ca2+-binding PEF(L) (dark green) do-
mains. The μ-calpain peptide N2 is colored blue. The side chains of
two N2 residues, D346 and D351, formed salt bridges with residues
K234 and K230, respectively, in the PC2 domain. The μ-calpain pep-
tide N9 is colored yellow. In this site, the side chains of R469 andFig. 7. HIV-conjugated μ-calpain peptides inhibit AIF truncation. HIV-conjugated
μ-calpain peptides (HIV-Nμ, ﬁnal concentration; 50 μM), as shown in Table 2, and
calpain inhibitors (50 μM calpeptin and 150 μM PD150606) were pretreated with iso-
lated rat liver mitochondria, and treated and solubilized as described in the Materials
and methods. The solubilized mitochondrial proteins were separated by SDS-PAGE,
and AIF truncation was examined by immunoblotting (30 μg protein/lane). Proteolytic
processing of AIF in the presence of Ca2+ (lane 3) was completely blocked by calpeptin
(lane 4) and PD150606 (lane 5). HIV-Nμ (lane 6) signiﬁcantly reduced AIF truncation.
Treatment with HIV-1 tat peptide alone did not inhibit AIF truncation (lane 7). The
solid and open arrowheads indicate 62-kDa intact and 57-kDa truncated AIF, respec-
tively. Results are representative of three independent experiments.
Fig. 8. Conservation and plasticity of 15 human calpains. The aa sequences of 15 human calpains were aligned using the L-INS-i procedure provided in MAFFT software (http://mafft.
cbrc.jp/alignment/server/). The accession numbers for CAPN1-3, 5–16, respectively, are: NP_005177, NP_001739, NP_000061, NP_004046, NP_055104, NP_055111, NP_001137434,
NP_006606, NP_004046, NP_008989, NP_653292, NP_653176, NP_001138594, NP_005623 and EAW47827. Sequences corresponding to the protease core domain 2 (PC2;
the C-terminal half of the protease (CysPc) domain) and the C2-like domain (domain III; C2L) are shown here. Numbers above the sequences correspond to amino acid
residue (aar) numbers of CAPN1 (dots or vertical lines mark at every 10th residue). Numbers on the both sides of the sequences indicate the ﬁrst and the last aar numbers
of the corresponding line of each calpain isoform sequence. The identity of each aar among isoforms is indicated by either reversed letters (100%), orange marking (≥50%),
or none (b50%). Residues that compose the Ca2+-binding site (CBS-2) in the PC2 domain are indicated by green asterisks. Arrowheads indicate the most conserved His and Asn
residues in the catalytic triad of calpains. The PC2 domain is highly conserved among these isoforms, whereas C2L domain is less conserved. μ-Calpain peptides N2, N2-10-2, and
N9 are indicated with blue boxes. μ-calpain peptide N2 corresponds to the linker region between PC2 and C2L domains. The homology of the N2 and N9 peptides regions was
relatively low between μ-calpain catalytic subunit (CAPN1) and other calpain isoforms.
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PC2 domain.3.9. Intravitreal injection of HIV-Nμ inhibits apoptosis of retinal
photoreceptors in RCS rats
Our previous study revealed that mitochondrial calpains are acti-
vated at postnatal day (PND) 25 in the retina of RCS rats, mitochon-
drial calpain activates AIF to induce photoreceptor apoptosis, and
intravitreal injection of calpain inhibitors (ALLN and PD150606)
reduced apoptosis by ~50% [15]. Therefore, we determined the inhib-
itory effects of an HIV-conjugated μ-calpain peptide [μ-N2-10-2
(HIV-Nμ) as shown in Table 2] on apoptosis of retinal photoreceptors
in RCS rats. The results of this study are shown in Fig. 10. TUNEL
staining revealed marked changes in the number of apoptotic cells
in the retinal photoreceptor layer after intravitreal injection of 2 μl
of 20 mM HIV-Nμ, 4 mM PD150601, or vehicle alone (PBS) at PND
25, and the eyes were enucleated at PND 28. TUNEL staining showed
that the number of apoptotic photoreceptor nuclei in the outer nucle-
ar layer was decreased by intravitreal injection of PD150606. HIV-Nμ
also dramatically inhibited photoreceptor apoptosis, and its effects
did not differ between the superior and inferior halves of the retina.3.10. Delivery of HIV-Nμ into retinal cells
We next determined whether HIV-Nμ was efﬁciently delivered
into the retinal cells following intravitreal injection (Fig. 10C). In
this study, 2 μl of 20 mM HIV-Nμ was injected at PND 25, and
the eyes were enucleated at PND 26. HIV-Nμ was detected on
retinal sections by immunoﬂuorescence with anti-HIV1 tat anti-
body. Notably, HIV-Nμ was present in the photoreceptor seg-
ment, outer nuclear layer, inner nuclear layer and ganglion cell
layer.
3.11. Intravitreal injection of HIV-Nμ preserves retinal function in RCS
rats
Considering the effects on inhibiting apoptosis, we next deter-
mined the effects of HIV-Nμ on preservation of retinal function in
RCS rats, using electroretinography (ERG) (Fig. 11). RCS rats were
treated with 20 mM HIV-Nμ, 4 mM PD150606, or vehicle alone
(PBS) at PND 25, and scotopic ERGs were recorded at PND 28 days.
Although a ﬂash ERG was performed on a dark-adapted eye, the re-
sponse was primarily from rod system. Sufﬁciently bright ﬂashes elic-
it ERGs containing an a-wave (initial negative deﬂection), followed by
a b-wave (positive deﬂection). The a-wave is derived from
Fig. 10. TUNEL staining of retinal sections of RCS rats treated with HIV-conjugated
μ-calpain peptide (HIV-Nμ). (A) RCS rats received an intravitreal injection of 2 μl of
20 mM HIV-Nμ (GRKKRRQRRRPPQ-PDALKSRTLR), 4 mM PD150606, or vehicle alone
(PBS) at postnatal day (PND) 25. The eyes were enucleated at PND 28. Retinal sections
were stained with TUNEL (green) and DAPI (blue). The number of apoptotic photorecep-
tor nuclei in the outer ONLwas drastically decreased by theHIV-Nμ. (B) Quantitative anal-
ysis of the number of TUNEL-positive cells in the ONL at PND 28. Photoreceptor apoptosis
was signiﬁcantly inhibited by HIV-Nμ. Data are expressed as means±SD [n=12 eyes (6
rats) per group]. ***Pb0.001 versus vehicle (ANOVA). (C) Delivery of HIV-Nμ into retinal
cells following intravitreal injection. RCS rats received an intravitreal injection of 2 μl of
20 mM HIV-Nμ at PND 25. The eyes were enucleated at PND 26 and retinal sections
were stained with anti-HIV1 tat antibody (red) and DAPI (blue). HIV-Nμ was present in
the PS, ONL, INL and GCL. Abbreviations: GCL, ganglion cell layer; INL, inner nuclear
layer; ONL, outer nuclear layer; PS, photoreceptor segment.
Fig. 9. Three-dimensional (3D) ribbon structure of active human m-calpain and the re-
gions targeted by the μ-calpain peptides generated using MolFeat software version 4.5.
(A) The large and small subunits of active m-calpain are shown in the 3D structure. The
PDB accession number for active human m-calpain is 3DF0. The large subunit com-
prises the catalytic protease (CysPc) domains PC1 and PC2 (red), C2-like Ca2+-binding
(C2L) domain (domain III) (silver), and the Ca2+-binding PEF domain (dark green).
The Ca2+-binding PEF domain in the 30-kDa S-chain associates with the large subunit
(light green). The side chains of the catalytic triad residues are circled in black. Blue
spheres indicate Ca2+-binding sites. The regions corresponding to μ-calpain peptides
N2 and N9 are colored green and yellow, respectively. The side chains of D346 and
D351 in μ-calpain peptide N2 form salt bridges with residues K234 and K230, respec-
tively, in PC2 domain. The side chains of R469 and R474 in μ-calpain peptide N9
form salt bridges with residues E202, D206 and E213 in PC2 domain. (B) Magniﬁed
view of the salt bridges shown in (A).
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Fig. 11. Effects of HIV-Nμ on scotopic electroretinography (ERG) in RCS rats. RCS rats were treated with 2 μl of 20 mM HIV-Nμ (GRKKRRQRRRPPQ-PDALKSRTLR) (●), 4 mM
PD150606 (◆), or vehicle alone (PBS; ■) at postnatal day (PND) 25. Scotopic ERGs were recorded at PND 28 days. (A) Representative ERG traces. The arrowheads represented
the time at which eyes were exposed to light. The HIV-Nμ-treated retina showed visible preservation of a- and b-wave amplitudes compared with the non- or vehicle-treated retina
at 1000 lx. (B) Mean amplitudes of ERG-recorded a- and b-waves. The HIV-Nμ-treated retina showed signiﬁcant preservation of a-wave amplitude compared with the
vehicle-treated retina at 30, 300, and 1000 lx. The preservation effect on b-wave amplitude by HIV-Nμ was signiﬁcantly compared with the vehicle-treated retina at 1000 lx.
Data are expressed as means±SD [n=12 eyes (6 rats) per group]. *Pb0.05 and **Pb0.01 versus vehicle (ANOVA).
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duced by the Müller cells. The HIV-Hμ-treated retina showed visible
preservation of a- and b-wave amplitudes compared with the non-
or vehicle-treated retina at 1000 lx (Fig. 11A). To clarify the differences
of ERG responses among HIV-Nμ-, PD150606-, or vehicle-treatments,
we plotted the amplitudes of the a- and b-waves (Fig. 11B). The
HIV-Nμ-treated retina showed signiﬁcant preservation of a-waveamplitude compared with the vehicle-treated retina at 30, 300, and
1000 lx (Pb0.01). However, we observed that PD150606-treated retina
preserved a-wave amplitude only at 1000 lx (Pb0.05). The preserva-
tion effect on b-wave amplitude by HIV-Nμwas signiﬁcantly compared
with the vehicle-treated retina at 1000 lx (Pb0.05). These results
suggested that HIV-Nμ has a greater ability in preserving retinal func-
tion than PD150606.
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degeneration in RCS rats
We applied eye drops containing HIV-Nμ to RCS rats and exam-
ined the protective effects of HIV-Nμ on photoreceptor degeneration.
We placed eye drops containing 40 mM HIV-Nμ, 40 mM HIV-Nμ
scramble, or vehicle alone (PBS) on the eyes of RCS rats from PND
14 to PND 27; eyes were enucleated at PND 28. The results of this
study are shown in Fig. 12. The number of TUNEL-positive cells in
the ONL was reduced by ~50% in HIV-Nμ-treated retinas. Quantitative
analysis of the number of TUNEL-positive cells showed that HIV-Nμ
signiﬁcantly prevented photoreceptor apoptosis (Pb0.01).
4. Discussion
The purpose of the present study was to identify and characterize
peptides capable of inhibiting mitochondrial μ-calpain and preventing
AIF truncation. We demonstrated that the peptide corresponding toFig. 12. TUNEL staining of retinal sections of RCS rats treated with topical eye drops
containing HIV-Nμ. (A) Eye drops containing PBS (vehicle alone), 40 mM HIV-Nμ
(GRKKRRQRRRPPQ-PDALKSRTLR), or 40 mM HIV-Nμ scramble (GRKKRRQRRRPPQ-
ASLRLDRPTK) were administered from PND 14 to PND 27. Eyes were enucleated at
PND28. Retinal sections were stained with TUNEL (green) and DAPI (blue). The num-
ber of TUNEL-positive cells in the ONL was reduced by about 50% in HIV-Nμ-treated
retinas. (B) Quantitative analysis of the number of TUNEL-positive cells in the ONL at
PND 28. Photoreceptor apoptosis was signiﬁcantly inhibited by HIV-Nμ. Data are
expressed as means±SD [n=20 eyes (10 rats per group)]. **Pb0.01 versus vehicle
(ANOVA).the links between CysPC and C2L domains in μ-calpain potently
inhibited the activity of mitochondrial μ-calpain. The present study
also revealed that the peptide prevented AIF truncation, suggesting
that it may be useful to treat AIF-induced disorders, such as retinal de-
generation and cerebral ischemia.
The μ-calpain peptides N2 and N9 inhibited the activity of mito-
chondrial μ-calpain (IC50; 892 and 498 nM, respectively) (Fig. 3).
We previously found that the ERp57 and Grp75 chaperones bind to
mitochondrial μ- and m-calpains, respectively [10,11]. We ﬁrst hy-
pothesized that the μ-calpain peptides competitively inhibit mito-
chondrial μ-calpain–ERp57 interaction, and induce a loss of stability
and activity of the mitochondrial μ-calpain. In fact, we found that
μ-calpain peptides N2 and N9 induced the degradation of mitochon-
drial μ-calpain (Fig. 4). These results suggest that μ-calpain peptides
N2 and N9 could access the binding regions of mitochondrial
μ-calpain and ERp57, and hence competitively inhibit the interac-
tions, resulting in the loss of stability and activity. The calpain pep-
tides identiﬁed in the present study were consistent with the salt
bridges between the CysPC and C2L domains (Fig. 9). Calpain mole-
cules form several salt bridges and the salt links play signiﬁcant
roles in calpain activation. Hosﬁeld et al. reported that abolishing
the salt bridge between residues K234 and E504 (i.e., the CysPC–C2L
domain linker) destabilized the calpain molecule and inactivated
the enzyme [39]. They also found that the K10–D148 salt bridge
(i.e., the domain I–CysPC domain linker) modulated calpain activa-
tion [40]. Moldoveanu et al. reported that elimination of the R104–
E333 salt bridge had a more drastic effect on enzyme action, particu-
larly at low Ca2+ concentrations [41]. In the present study, μ-calpain
peptides N2 and N9 prevented calpain activation, and these peptides
contain the salt bridges between PC2 and C2L domains (Figs. 2, 3 and
9). And μ-calpain peptides N2 and N9 caused degradation of the
large subunit of mitochondrial μ-calpain (Fig. 4). Therefore, we spec-
ulated that these peptides could disrupt the mitochondrial
μ-calpain–ERp57 interaction, and facilitate the loss of stability and
activity. Disruption of this interaction would lead to conformational
changes in the protease domains (i.e., PC1 and PC2 domains) and
hence inactivate mitochondrial μ-calpain. From these results, we
think that the binding of ERp57 to the salt bridges D346–K234,
D351–K230, R469–E202/E206 and R474–E213 is critical for the sta-
bilization and activation of mitochondrial μ-calpain.
In the present study, the HIV-conjugated μ-calpain peptide
(HIV-Nμ, ﬁnal concentration; 20 mM) inhibited apoptosis of retinal
photoreceptors and preserved retinal function in RCS rats, an animal
model of retinitis pigmentosa (Figs. 10–12). We previously found
that mitochondrial calpains were activated in the early stage of reti-
nal photoreceptor apoptosis in RCS rats [15]. In that study, we
found that intravitreal injection of calpain inhibitors, such as ALLN
and PD150606, at the time of mitochondrial calpain activation could
inhibit photoreceptor apoptosis. However, we were concerned that
these calpain inhibitors would also prevent the physiologic functions
of retinal cells, including photoreceptors, Müller cells, ganglion cells,
bipolar cells and amacrine cells, because these calpain inhibitors
block mitochondrial calpains as well as cytosolic calpains. Cytosolic
μ- and m-calpains modulate many essential physiologic processes
[1]. Notably, the HIV-Nμ peptide used in the present study did not in-
hibit the activity of cytosolic μ- or m-calpains (Fig. 3). Furthermore, as
shown in Figs. 10 and 11, HIV-Nμ (ﬁnal concentration; 20 mM) elicit-
ed greater effects than PD150606 (ﬁnal concentration; 4 mM) in
terms of inhibiting retinal photoreceptor apoptosis and preservation
of retinal function. Therefore, we think that HIV-Nμ may offer func-
tional improvements in RP with few adverse effects on the physiolog-
ical functions of retinal cells.
The most striking result of the present study was that topical
application of eye drops containing HIV-Nμ (ﬁnal concentration;
40 mM) protected against retinal degeneration in RCS rats. Topical
eye drop application is much easier and safer than intravitreal
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and adherence to treatment.
Our goal in future studies is to develop HIV-Nμ peptides that can
be used for the treatment of AIF-induced diseases such as cerebral is-
chemia [14], cardiac ischemia [16], epilepsy [42], Alzheimer disease
[21], cisplatin nephrotoxicity [22] and retinal degeneration [13,15].
In retinal diseases, the calpain-dependent cell death pathway has
been shown to be involved in glaucoma [43–45], ischemia [46], gluta-
mate excitotoxicity [47], diabetic retinopathy [48] in addition to pho-
toreceptor degeneration [15,49]. Of note, in axonal damage-induced
retinal ganglion cell (RGC) death, including glaucoma and diabetic
optic neuropathy, calpains are activated and the calpain inhibitor
SNJ-1945 was found to prevent RGC death [45]. Therefore, we suggest
that the HIV-Nμ is a novel therapeutic drug that could be used to treat
vision-threatening diseases, such as glaucoma and diabetic axonal at-
rophy, in addition to retinitis pigmentosa.
5. Conclusion
Our results demonstrated that the peptide inhibitor of mitochon-
drial μ-calpain, HIV-Nμ, offers a new modality for treating retinitis
pigmentosa.
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